- An international survey of 2,002 people found that people who had previously had COVID-19 experienced “significantly increased incidence and severity” of side effects after the COVID-19 vaccine
- Dr. Hooman Noorchashm has repeatedly warned the FDA that “clear and present danger” exists for those who have had COVID-19 and subsequently get vaccinated
- At issue are viral antigens that remain in the body after a person is naturally infected; the immune response reactivated by the COVID-19 vaccine may trigger inflammation in tissues where the viral antigens exist
- The inner lining of blood vessels, the lungs and the brain may be particularly at risk of such inflammation and damage, which could lead to major thromboembolic complications
- Noorchashm believes that people should be screened for SARS-CoV-2 viral proteins prior to COVID-19 vaccination, while vaccination should be delayed for people with symptomatic or asymptomatic COVID-19 infections, as well as those who have recently recovered from the virus
In their race to vaccinate the entire U.S. adult population, health officials are urging everyone to get a COVID shot, regardless of whether or not they’ve already been infected with SARS-CoV-2, the virus that causes COVID-19, and spending billions of dollars in taxpayer funded propaganda to convince people to get the vaccine.
This is an important distinction, however, with at least one scientist warning the U.S. Food and Drug Administration that “clear and present danger” exists for those who have had COVID-19 and subsequently get vaccinated.
That scientist — Dr. Hooman Noorchashm, a cardiac surgeon and patient advocate — warned the FDA that prescreening for SARS-CoV-2 viral proteins may reduce the risk of injuries and deaths following vaccination, as the vaccine may trigger an adverse immune response in those who have already been infected with the virus.1
Unfortunately, health agencies continue to assert that everyone should get vaccinated, even if they’ve already acquired natural immunity via previous infection.